Assetwise PCL (SET: ASW) partners with Tokyo Tatemono, Japan’s oldest developer ACN Newswire

Assetwise PCL (SET: ASW) partners with Tokyo Tatemono, Japan’s oldest developer

September 15, 2022
BANGKOK, Sep 15, 2022 - (ACN Newswire via SEAPRWire.com) - Assetwise PCL (SET: ASW), a leading real estate developer for lifestyle with the 'We Build Happiness' concept, has formed an alliance with Tokyo Tatemono, the oldest real estate developer in Japan with a 126-year history, to jointly develop the Atmoz Oasis Onnut condominium project, worth THB 2,200 million. A synergistic weaving of the partners' long-accumulated know-hows and experience in real estate development, the plan will bring value to the project, upscaling the quality of life with "luxury resort" style, while catering to the needs of both foreign and Thai customers.Assetwise (SET: ASW) and Tokyo Tatemono (TSE: 8804) launch their Joint Venture to develop the Atmoz Oasis Onnut condominium project at a signing ceremony in Bangkok. [Image: Assetwise]Mr. Kromchet Vipanpong, CEO of Assetwise PCL, announced the expansion plan and partneriship with Tokyo Tatemono Co. Ltd, a TSE-listed developer, at the signing ceremony. ASW holds 51% and Tokyo Tatemono holds 49% in the joint venture (JV) to develop the Atmoz Oasis Onnut condominium project, with the concept "The Oasis Within City Resort Lost in the Garden". Residences nestled in nature reflect this concept within the Onnut community, where the project will have 1,110 units worth THB 2,200 million.A major Japanese developer with a storied history, Tokyo Tatemono has developed many types of real estate that capture the needs of the time, with the spirit of the pioneer. The Atmoz Oasis Onnut project is comparable to a large oasis covering three rai of land to create residences in a luxury resort style. The collaboration between ASW and Tokyo Tatemono invites synergy between Tokyo Tatemono's extensive experience and ASW's unique design to uplift the quality of life, which adds real value for residents.Tokyo Tatemono (TSE: 8804) is a TSE-listed real estate developer with total assets at the end of 2021 of JPY1,650 billion, or approx. THB438 billion. The company develops residential and commercial properties at many popular locations in Japan. This joint venture is a manifestation of trust between the two partners."This is an important step for both companies in jointly developing a real estate project in Thailand that will raise the quality of living for Thai people as well as extend a welcome mat to foreign residents," said Mr Kromchet. "The fact that Tokyo Tatemono collaborates with our company demonstrates our potential as a leading developer with creative products to meet the needs of the new generation's lifestyle. We have extensive development experience of both vertical and horizontal properties in all segments. Our outstanding facility designs are created to satisfy residents' lifestyles. ASW is confident that our new investment will bring knowhows from our partner to build a foundation in real estate development for a sustainable growth."Mr Fumio Tajima, Managing Officer and Head of the Overseas Business Division, Tokyo Tatemono Co., Ltd., said "The real estate business in Thailand shows immense potential and room to grow, particularly public transit development projects, due to city expansion such as electric trains and expressways. Through joint ventures with reliable partners, the company is determined to develop properties that will contribute to raising the standard of living for residents and help to make the region more attractive and valuable, as we have experienced in Japan."Assetwise, Mr Tajima adds, "Is a real estate company managed by a new generation of developers who have broad vision and run the business towards steady growth. The proof of this success is its more than 44 quality projects. For its part, Tokyo Tatemono will bring its business model under its corporate philosophy "Trust beyond the era" into the collaboration to synergize with ASW's "We Build Happiness" concept to create opportunities and growth together."In operating its real estate business, ASW aims to develop both vertical and horizontal projects in high-potential locations under the "We Build Happiness" concept. Currently, the company has completed development of 44 condominium and housing estate projects under brands that are created to bring happiness appropriate to all lifestyles, including KAVE, ATMOZ, MODIZ, ESTA, and THE HONOR brands, with a total investment of THB46,700 million. The overall development covers 32 completed and ready-for-occupancy projects as well as 12 others under development and open for sales. Its current backlog is valued at THB9,218 million and revenues are to be recognized on a continuous basis.Assetwise PCL [SET: ASW]Website: https://investor.assetwise.co.th/enReleased for Assetwise PCL by MT Multimedia Co LtdPipop (Top), T: +66 81 929 8864; E: pipop.k@mtmultimedia.comTokyo Tatemono Co Ltd [TSE: 8804]Website: https://www.tatemono.com/english/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Eros Investments, Xfinite and Calvin Cheng partner to launch XelebX, World’s First Metaverse Members-Only Influencer Fan Club

September 14, 2022
- Members will get access to the XelebX club through tradable NFTs- XelebX will launch with a community of 200+ million existing fans across the Eros ecosystemMUMBAI, INDIA, Sept 14, 2022 - (ACN Newswire via SEAPRWire.com) - Eros Investments, a leading Global Media, Entertainment & Technology portfolio of ventures, and Xfinite, a decentralized entertainment ecosystem, have partnered with veteran entertainment and tech entrepreneur Calvin Cheng, to launch ‘XelebX', the world's largest Web 3.0 members-only celebrity fan club. The partnership will introduce over 200 million existing fans of global influencers and celebrities associated with Eros' ecosystem and its group companies to the new metaverse with NFTs and Fan Tokens.XelebX will be accessible only through NFT memberships. The NFT membership holders will get access to various benefits, including exclusive access to virtual meets with the influencers, exclusive content, virtual backstage passes, and celebrity NFT collectibles.XelebX, at a later stage, will launch fan tokens that track an influencer's popularity and will be tradeable on major exchanges allowing holders across fandoms to trade and exchange value freely. This will also enable influencers and celebrities to collaborate and grow their fanbase in a way native to Web 3.0 interoperability and composability.Existing Community Key to SuccessCalvin Cheng says, "Web 3 is all about community building. Other platforms have tried this in the past. They built the tech but struggled to build the community – the key to Web 3's success. We already have the tech expertise and an amazing community of hundreds of millions of fans. We will now onboard them into the Metaverse using the latest digital asset and Web 3 technologies."Next Evolution of Media and EntertainmentKishore Lulla, Chairman, Eros Investments, says, "Over five decades, Eros has built one of the largest media and entertainment businesses enthralling millions of fans and launching some of the biggest stars in India. One of the key reasons for our success is our ability to embrace change - from film to TV to the Internet and now Web 3.0 and readiness to lead it from the front. The metaverse and the immersive Internet are the technological tides that will carry us forward for the next 50 years. Eros is committed to being at the forefront of its adoption."Swaneet Singh, CEO of Xfinite, says, "With Xfinite, Eros has already gained invaluable experience in media built upon virtual assets and the blockchain. XelebX is the next natural innovation to bring the global community of entertainment fans into the metaverse and unlock immersive interaction with the influencers they follow."Xfinite's partner Mad Influence, a leading influencer marketing company, has joined XelebX, the world's first Metaverse Members-Only Influencer Fan Club. Various celebrities from Mad Influence have associated with XelebX for the launch. Gima Ashi (Garima Chaurasia), an Indian-origin actor, model, and social media influencer with 14.6 million followers on Instagram and a part of Mad Influence's ecosystem, says, "I am super excited to join XelebX. The platform will facilitate better engagement with my fans and allow both fans and I to monetise our relationships through digital assets like NFTs and Fan tokens."About Eros InvestmentsEros Investments is a venture with assets in media, sports, blockchain, digital commerce and gaming. Its portfolio companies include Eros Media World, Eros Now, Xfinite, EXR, and Eros Innovations. Disruption is at the heart of Eros Investments, and its core culture is deeply rooted in next-generation intellectual properties with technology as the driving force. Its blockchain, sports, and entertainment ventures have been game changers with a solid first mover advantage. Eros Investments is a future-ready organization committed to developing the Web 3.0 ecosystem with a mission to make the world of entertainment better through innovation and diversity.About XfiniteXfinite is a decentralised entertainment ecosystem where users turn their time and engagement into rewards, brands advertise with trust and creators build economies. Xfinite achieves this by democratising premium content and NFTs through products such as Mzaalo and MzaaloNFT. Mzaalo is a play-to-earn VoD platform offering millions of users of premium content across 12,000+ movies, music, originals, and live TV. Users redeem earned tokens across 600+ established brands, merchandise, digital goods, games, and celebrity experiences. It is on the iOS, Play Store, and JioStore, and provides entertainment to millions of Daily Hunt, Josh, Eros Now users, SpiceJet and Daimler travellers. Xfinite's soon-to-be-launched NFT marketplace, MzaaloNFT will connect consumers and NFT collectors to native and globally acclaimed artists, celebrities, athletes, millions of digital collectables, and more. The ecosystem is powered by the Xfinite Entertainment Token ($XET). $XET is available on BitMart, MEXC, Tinyman and Algofi as well as on high-performing staking platforms like Yieldy. It is also the only media-entertainment-based blockchain platform to get the Virtual Asset License from the Dubai government.www.xfinite.iowww.mzaalo.comwww.mzaaloNFT.comAbout Calvin Cheng Web 3 HoldingsCalvin Cheng is currently the Chairman of listed Chinese EdTech firm ReTech Technology Co, which he led to an Initial Public Offering, together with other high-profile investors from China. ReTech's shareholders include several co-founders of Alibaba, as well as founders of other major Chinese tech companies. Prior to ReTech, Cheng was the Head of Elite Model Management for Asia. He was also the licensee for Ford Supermodel of The World for China, Singapore and Malaysia. Cheng launched a media investment fund with one of China's largest film and media group, The Bona Film Group.In Singapore, Cheng was the founding director of Lumina-Looque Group, which organises fashion events for global luxury brands like LV, Moncler and Ferrari. Lumina was also involved in organising the launch of Dubai Meydan City. Cheng is the former appointed Member of Singapore's Parliament and Young Global Leader of the World Economic Forum.Calvin Cheng Web 3 Holdings was the first NFT and Fan Token company to be granted a license by Dubai Virtual Asset Regulatory Authority (DVARA).For more information, contact:Chi-an ChangDirector, Public Relations (Singapore)chi-an@financialpr.com.sgT: (65) 6438 2990 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma JCN Newswire

Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

September 12, 2022
TOKYO and RAHWAY, N.J., Sep 12, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 trial investigating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Rahway, NJ, USA versus LENVIMA monotherapy, as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). Results are being presented during a proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2022, being held in Paris, France and virtually from Sept. 9-13 (abstract #LBA34).In the final analysis of the trial, there was a trend toward improvement for one of the study's dual primary endpoints, overall survival (OS), for patients treated with LENVIMA plus KEYTRUDA versus LENVIMA monotherapy; however, the results did not meet statistical significance per the pre-specified statistical plan (HR=0.84 [95% CI: 0.71-1.00]; p=0.0227). The median OS was 21.2 months (95% CI: 19.0-23.6) for LENVIMA plus KEYTRUDA and 19.0 months (95% CI: 17.2-21.7) for LENVIMA monotherapy. Additionally, treatment with LENVIMA plus KEYTRUDA resulted in a trend toward improvement in the trial's other dual primary endpoint of progression-free survival (PFS) versus LENVIMA monotherapy; however, the results did not meet the pre-specified threshold at the first interim analysis for statistical significance (HR=0.87 [95% CI: 0.73-1.02]; p=0.0466). "The LEAP-002 trial reflects our research strategy to build on evolving standards of care to further improve outcomes for more people with unresectable hepatocellular carcinoma," said Dr. Gregory Lubiniecki, Vice President, Global Clinical Development, Merck & Co., Inc., Rahway, NJ, USA Research Laboratories. "The median overall survival of 21.2 months seen with KEYTRUDA plus LENVIMA provides critical insights for further research into the potential role of this combination.""While the outcome is not what we had hoped, it is important for us to see that patients in the trial treated with LENVIMA monotherapy had a median overall survival of 19.0 months," said Corina Dutcus, M.D., Senior Vice President, Clinical Research, Oncology at Eisai Inc. "Findings from the LEAP-002 trial will not only help advance our understanding and application of LENVIMA plus KEYTRUDA across our clinical development program but will also provide physicians with additional information on LENVIMA monotherapy's use in unresectable hepatocellular carcinoma, where it is currently approved as a treatment option in multiple regions around the world, including the U.S., the European Union (EU), Japan and China."LENVIMA monotherapy is approved for the first-line treatment of patients with uHCC in the U.S., the EU and China and for patients with uHCC in Japan. The approval of LENVIMA was based on results of the Phase 3 REFLECT trial, which evaluated the efficacy and safety of LENVIMA versus sorafenib for the first-line treatment of patients with uHCC.LENVIMA (marketed as KISPLYX for renal cell carcinoma [RCC] in the EU) plus KEYTRUDA is approved in the U.S., the EU and Japan for the treatment of certain types of advanced endometrial carcinoma and advanced RCC. Eisai and Merck & Co., Inc., Rahway, NJ, USA are studying the LENVIMA plus KEYTRUDA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in multiple tumor types, including but not limited to endometrial carcinoma, HCC, melanoma, non-small cell lung cancer, RCC, head and neck cancer, colorectal cancer, gastric cancer and esophageal cancer, across more than 15 clinical trials. LEAP-002 study design and final analysis results (abstract #LBA34)LEAP-002 is a multicenter, randomized, double-blinded, active-controlled Phase 3 trial (ClinicalTrials.gov, NCT03713593(New Window)) evaluating LENVIMA plus KEYTRUDA versus LENVIMA monotherapy for the first-line treatment of adult patients with uHCC. Patients were randomized 1:1 to receive LENVIMA (12 mg orally once daily [for patients with screening body weight of at least 60 kg] or 8 mg orally once daily [for patients with screening body weight less than 60 kg]) plus KEYTRUDA (200 mg intravenously [IV] on Day 1 of each three-week cycle); or LENVIMA (12 mg orally once daily [for patients with screening body weight of at least 60 kg] or 8 mg orally once daily [for patients with screening body weight less than 60 kg]) plus saline placebo (IV administered on Day 1 of each three-week cycle). LENVIMA was administered until progressive disease or unacceptable toxicity. KEYTRUDA/placebo was administered for up to 35 cycles (approximately two years).The dual primary endpoints were PFS, as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1; RECIST v1.1 has been modified for this study to follow a maximum of 10 target lesions in total and a maximum of five target lesions per organ), and OS. Objective response rate (ORR), as assessed by BICR per RECIST v1.1, was a key secondary endpoint. The trial was designed with two interim analyses and a final analysis for OS. Pre-specified efficacy boundaries were one-sided p=0.002 for PFS at interim analysis 1 and p=0.0185 for OS at the final analysis.As of the data cut-off for the final analysis (June 21, 2022), a total of 794 patients were enrolled and treated, with a median follow-up of 32.1 months (range, 25.8-41.1). A total of 534 OS events had occurred, with 36 patients (9.1%) in the combination arm and 24 patients (6.1%) in the LENVIMA monotherapy arm remaining on study treatment.The median OS was 21.2 months (95% CI: 19.0-23.6) for LENVIMA plus KEYTRUDA versus 19.0 months (95% CI: 17.2-21.7) for LENVIMA monotherapy at the final analysis. The median PFS was 8.2 months (95% CI, 6.4-8.4) for LENVIMA plus KEYTRUDA versus 8.0 months (95% CI: 6.3-8.2) for LENVIMA monotherapy at the first interim analysis and 8.2 months (95% CI: 6.3-8.3) versus 8.1 months (95% CI: 6.3-8.3), respectively, at the final analysis. The ORR was 26.1% (95% CI: 21.8-30.7) for LENVIMA plus KEYTRUDA versus 17.5% (95% CI: 13.9-21.6) for LENVIMA monotherapy at the final analysis. Median duration of response was 16.6 months (range, 2.0+ to 33.6+) in the KEYTRUDA plus LENVIMA arm versus 10.4 months (range, 1.9 to 35.1+) in the LENVIMA monotherapy arm at the final analysis.The safety profile of LENVIMA plus KEYTRUDA was consistent with previously reported data on the combination. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 61.5% of patients treated with LENVIMA plus KEYTRUDA versus 56.7% of patients treated with LENVIMA monotherapy. Grade 5 TRAEs occurred in 1.0% of patients treated with LENVIMA plus KEYTRUDA versus 0.8% of patients treated with LENVIMA monotherapy. In patients treated with LENVIMA plus KEYTRUDA, the five most common TRAEs of any grade were hypertension (43.3%), diarrhea (40.3%), hypothyroidism (40.0%), palmar-plantar erythrodysesthesia (PPE) syndrome (33.2%) and proteinuria (30.6%). In patients treated with LENVIMA monotherapy, the five most common TRAEs of any grade were hypertension (46.8%), hypothyroidism (35.7%), proteinuria (34.9%), diarrhea (33.9%) and PPE syndrome (30.6%). Post-study systematic anti-cancer treatments were given for 44.1% of patients receiving LENVIMA plus KEYTRUDA versus 52.1% of those receiving LENVIMA monotherapy.Eisai Co., Ltd.Public Relations:+81-(0)3-3817-5120Merck & Co., Inc., Kenilworth, N.J., U.S.A.Media RelationsMelissa Moody: +1-(215) 407-3536Nikki Sullivan: +1-(718) 644-0730 Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
TOYOTA GAZOO Racing concludes a rocky Acropolis weekend JCN Newswire

TOYOTA GAZOO Racing concludes a rocky Acropolis weekend

September 12, 2022
Toyota City, Japan, Sep 12, 2022 - (JCN Newswire via SEAPRWire.com) - The TOYOTA GAZOO Racing World Rally Team has completed a very challenging weekend at the Acropolis Rally Greece without the overall results it desired but with some important points secured to maintain its advantage in the drivers' and manufacturers' championships.In its second running since returning to the FIA World Rally Championship calendar, the Acropolis lived up to its reputation with slippery and rocky roads and high temperatures providing a considerable challenge. For much of the weekend, the team was in contention for a podium position but those hopes ended early on the final morning when Elfyn Evans had to retire from fourth place after an engine-related issue on the road section to SS14.With this, the team's focus moved to the rally-ending Power Stage. Here, Kalle Rovanpera managed to set the second-fastest time to claim four bonus points. The championship leader experienced a trying weekend after sweeping the loose gravel roads on Friday before losing around 15 minutes on Saturday morning after damaging his car. However, his Power Stage drive ensures he still leads the drivers' championship by 53 points with three rounds remaining.Esapekka Lappi was running in second place on Saturday before he was slowed and forced to stop by a technical issue. Restarting on Sunday, he set the fifth-best time on the Power Stage. With the points scored by Rovanpera and Lappi for reaching the finish combined with those they claimed on the Power Stage, the team remains in the lead of the manufacturers' championship by 63 points.Takamoto Katsuta was the highest-finishing GR YARIS Rally1 HYBRID driver, completing his Acropolis Rally debut in sixth overall to maintain his unbroken scoring run in 2022 with TGR WRT Next Generation.For more information check https://toyotagazooracing.com/wrc/release/2022/rd10-day4/ and for the latest results please visit www.wrc.com.What's next?The WRC heads to Rally New Zealand (September 29 - October 2) for the first time in 10 years. The smooth gravel roads around the capital city Auckland on the country's North Island are hugely popular with drivers for their fast and flowing nature and considerable camber changes. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Next Block Expo Event Embraces Compliance with Blockpass ACN Newswire

Next Block Expo Event Embraces Compliance with Blockpass

September 9, 2022
HONG KONG, Sep 9, 2022 - (ACN Newswire via SEAPRWire.com) - On-Chain KYC(TM) provider Blockpass is excited to announce a partnership with Next Block Expo, one of the biggest industry events in Europe. This new partnership will see Blockpass CEO Adam Vaziri speaking at the Next Block Expo event in Berlin on November 23rd and 24th of this year. Those looking to attend should take advantage of the early discounts being offered.Next Block Expo is styled as 'The Blockchain Festival of Europe' and boasts an impressive 5000 attendees, 100+ sponsors & exhibitors, and 80+ speakers. The event promises to be a hotbed of activity with presentations, roundtables, workshops, pitch contests, hackathons, VC 'speed dating' and numerous side events. Topics being discussed and explored during the two day extravaganza cover all manner of crypto- and blockchain-related topics including DeFi, blockchain gaming, the metaverse and NFTs, scaling and infrastructure, Web3 discovery, fundraising and investing. Next Block Expo offers a chance for attendees to meet founders and CEOs of fast-growing startups, VCs, angel investors, advisors and blockchain experts that can elevate business to the next level.Blockpass is a digital identity verification provider which provides a one-click compliance gateway to financial services and other regulated industries. Through Blockpass, users can create, store, and manage a data-secure digital identity that can be used for an entire ecosystem of services, token purchases and access to regulated industries. For businesses and merchants, Blockpass is a comprehensive KYC & AML SaaS that requires no integration and no setup cost. You can set up a service in minutes, test the service for free and start verifying and on-boarding users. Currently with more than 500,000 verified user identity profiles, Blockpass facilitates instant onboarding, and to date over 3000 services have taken advantage of this opportunity to get access to users with reusable digital identity profiles."We're delighted to be getting back into the events scene with such an important company as Next Block Expo." said Adam Vaziri, Blockpass CEO. "We've always been determined to bring regulation and compliance to the widest possible audience and bring legitimacy to the blockchain ecosystem, and with the foresight of the Next Block Expo team in realizing the importance of compliance this promises to be a great place to do so.""Next Block Expo wants to focus on the future of Web3 - we are witnessing a new economy that is a combination of what Web3 already created and now traditional sectors are jumping in. So let's discuss, brainstorm and share our vision of the future. Compliance is the big and important part of it." said Tom Kopera, Next Block Expo Co-Founder.Blockpass has grown significantly in size and use since its inception, both in the number and range of users and organizations it has partnered with and the scope of its work. Blockpass continues to develop its digital identity protocol with updates and additions to improve the compliance experience. The existential need for DeFi projects to be regulatory compliant and the recent integrations have led to a surge in interest for Blockpass' On-chain KYC(TM) solution which promises to change the way blockchains enable compliance. Through its recent work with Animoca Brands, Blockpass is developing the ability to provide KYC where the delivery of the verification result is provably sent and shown on a blockchain without sharing the underlying data. This represents a significant step towards the future Blockpass hopes to bring about where identity verification can be proved without revealing any personal information at all. About BlockpassBlockpass, the pioneer of On-chain KYC(TM), is a fast, fully comprehensive KYC & AML screening software-as-a-service for blockchains, Crypto, Defi and other regulated industries. With Blockpass, you get an unmatched set of benefits for any compliance service that includes pay-as-you-go, no setup cost, no integration necessary, free testing, immediate launch and at the lowest cost. Blockpass' KYC ConnectTM platform enables businesses to select requirements for customer onboarding that can include ID authentication, face-matching, address checking, AML ongoing monitoring and/or screening of sanctions lists, politically exposed persons (PEP), and adverse media. Through Blockpass, end-users easily create a verified portable identity that they can control and re-use to onboard with any service instantly. By integrating with Chainlink Network - a decentralized oracle solution - last year, Blockpass introduced the first On-chain KYC(TM) solution that will service many blockchains in the years to come. Additionally, Blockpass' partnership with Animoca Brands has demonstrated how verification and adherence to standards can be proved on a blockchain without revealing any underpinning data - a significant boon for verifying Animoca Brands' NFT prize winners and a huge step towards securing the ecosystem of the Metaverse. The Blockpass App is available from the App Store and Google Play. For more information and updates, please visit and sign up to the following:Promotional video: https://youtu.be/SvO2cw3e-SIWebsite: http://www.blockpass.orgEmail: sales@blockpass.orgAbout Next Block ExpoNext Block Expo - The Blockchain Festival of Europe will be held in Berlin, 23-24 November 2022. NBX brings founders, investors and blockchain experts together to redefine & discover the future of web3. With the magnitude of 14.000m2 venue, 5.000 attendees, 100+ sponsors and 80+ speakers it aims to become one of the biggest industry events in Europe.The event is called "The Blockchain Festival of Europe" for a reason as it serves its participants 6 content tracks within multiple formats including: Presentations, Roundtables, Workshops, Pitch Contest, Hackathons, Speed Dating, Side Events and Expo.Networking opportunity backed by world-class event mobile app is the core value proposition for the attendees. Target audience of the event includes founders, developers, VCs, exchanges, market makers, launchpads, dApps, service suppliers and other industry participants.More resources:Promotional video: https://youtu.be/cgrkFpSbuNEWebsite: https://nextblockexpo.com/Deck: https://bit.ly/3ONX7je Contact for media: kacper@nextblockexpo.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
TheCapitalNet awarded Best Private Market FinTech Solutions Provider 2022 by Wealth & Finance International ACN Newswire

TheCapitalNet awarded Best Private Market FinTech Solutions Provider 2022 by Wealth & Finance International

September 8, 2022
MENLO PARK, CA & HYDERBAD, IN, Sep 8, 2022 - (ACN Newswire via SEAPRWire.com) - TheCapitalNet, Inc., a leading enterprise SaaS and financial technologies company, has been awarded Best Private Markets FinTech Solutions Provider 2022 by Wealth & Finance International. TheCapitalNet was recognized for transforming the private markets and private investments eco-system through technology, while focusing on PE, VC, CVCs, Angel Networks, Family Offices and M&As.Link: www.wealthandfinance-news.com/winners/thecapitalnet-inc/Wealth & Finance International provides fund managers and institutional and private investors around the world with the latest industry news across both traditional and alternative investment sectors. This recognition reinforces the belief that TheCapitalNet products are putting the best technologies to work while collaborating with stakeholders to enable what they do best: value nurturing and wealth creation."We are thrilled to be recognized by Wealth & Finance International," said Dr. Rakesh Bhatia, Founder and CEO of TheCapitalNet. "Every accolade brings its own set of responsibilities to our business, and we are committed to making TheCapitalNet even more worthy. This recognition allows us to reaffirm our beliefs, and further realize our vision of digitally enabling the stakeholders of this ecosystem globally," added Rakesh.About TheCapitalNetTheCapitalNet, with offices in Dallas and Silicon Valley in the USA and Hyderabad in India, is an Enterprise SaaS and knowledge media venture operating in the Private Investments, Innovation and Startup ecosystem. TheCapitalNet products drive the digital transformation journey by enabling business processes and making them smarter and more intelligent, thus redefining business operations, decision making and business outcomes:* TheInvestorNet (www.theinvestornet.com) - An application for private investors including PE/VC/Angel Networks/Family offices/CVCs to manage the end-to-end business operations with over two dozen investments firms spread across various countries globally,* TheIncubatorPro (www.theincubatorpro.com) - An end-to-end productivity suite for incubators, accelerators, and/or open/corporate innovation with 180+ incubators and accelerators spread across various countries globally,* TheBizPlanner (www.thebizplanner.com) - An application for Founders/Entrepreneurs to plan their business and connect with the private investment and innovation ecosystem, used by 17,000+ startups spread across 70+ countries globally, and* TheCapitalNet TV (www.thecapitalnet.tv) - A knowledge media that produces and shares global content focused on above mentioned ecosystem through knowledge sessions, news and trends, research reports, interviews, and discussions - with over millions of impressions across 110+ countries.Visit: www.TheCapitalNet.com, Email: marcom@thecapitalnet.comAbout Wealth & Finance InternationalWealth & Finance International is a quarterly publication dedicated to delivering high quality informative and up-to-the-minute global business content. It is published by AI Global Media Ltd, U.K., a publishing house that has reinvigorated corporate finance news and reporting.Developed by a highly skilled team of writers, editors, business insiders and regional industry experts, Wealth & Finance International reports from every corner of the globe to give readers the inside track on the need-to-know news and issues affecting banking, finance, regulation, risk, and wealth management in their region.Visit: www.wealthandfinance-news.com/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
HRC Signs Contracts with Tim Gajser and Rubén Fernández JCN Newswire

HRC Signs Contracts with Tim Gajser and Rubén Fernández

September 7, 2022
TOKYO, Sep 7, 2022 - (JCN Newswire via SEAPRWire.com) - Honda Racing Corporation (HRC) announced that it has renewed its contract with Tim Gajser (25 years old, Slovenia), who currently competes in the FIM(1) Motocross World Championship premier MXGP class (450cc class) for Team HRC, Honda's factory team(2), and newly signed a contract with Rubén Fernández (23 years old, Spain). Both riders are signed on for multiple years starting in 2023.Tim Gajser (left), Rubén Fernández (right) and CRF450RAfter winning the Motocross World Championship title in the MX2 class (250cc) in 2015, Tim Gajser moved to the premier MXGP class the following year, and won the championship along with the Rookie of the Year title. Although he did not win the title for the following two years, Gajser won back-to-back championships in 2019 and 2020, and by claiming his fourth MXGP title this year, has won a total of five titles in the Motocross world championship.Rubén Fernández was third overall in the European Motocross Championship EMX250 class. Although he moved to MX2 in 2018, he moved back to EMX250 the following year. After moving full-time to MX2 in 2020, he finished ninth that year. In 2021, Fernández joined the MX2 team Honda 114 Motorsports, but from Round 17 moved to the premier MXGP class. This year, Fernández continued his full-time career in the MXGP class, ending up eighth in the championship, with two third-place finishes.- Tim Gajser "It was an easy decision to continue this amazing relationship with Team HRC. It is like a second-family to me and there is no other place where I feel it is such a nice environment. I always say "Happy Rider, Fast Rider" and working with everyone in Team HRC, from all the technicians in Japan, to my practice mechanic, to my physio, it is all so enjoyable and I always look forward to going racing. I have won five World Championships with Honda so I am extremely comfortable on-board the CRF450R and they always do such a great job with developing and improving the machine, so I know I'll be riding a bike capable of winning title number six in 2023. A huge thank you to all my supporters around the world, and I look forward to meeting you at Team HRC next year."- Rubén Fernández"It is a dream come true to be riding for Team HRC in the MXGP class. The team is the best in the paddock and having ridden the Honda for the past couple of years, I am very familiar with the bike, but now I'm very excited to get to ride the full factory machine next year. I am also excited to work alongside Tim, as I know I can learn a lot from a rider who is five-times champion of the world. I'd like to thank everyone who has supported me throughout my career, who got me to this point and I can't wait to show everyone what I am capable of. I now have the winter to prepare myself, and make sure I'm ready for the first gate-drop in 2023."- Koji Watanabe, Head of Corporate Communications Supervisory Unit,Honda Motor Co., Ltd. and President of Honda Racing Corporation"We are all very happy to have Tim signing again with Honda. He is an important figure for our company, and the perfect ambassador on and off the track. His achievement of winning five world titles is incredible and we hope that he can achieve even more goals riding on Hondas in the future. It is also exciting to have a new young rider Rubén Fernández joining the team. He has done well the past couple of years and this is the perfect time for him to make the switch to Team HRC. He has already had success on Honda, and now we hope we can build upon that in the coming years. I wish both riders the best of luck."(1) FIM: Fédération Internationale de Motocyclisme(2) Factory team: Racing team operated by manufacturer. In Honda's case, HRC-operated team. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Hitachi Acquires Key Industry 4.0 Systems Integrator — Flexware Innovation JCN Newswire

Hitachi Acquires Key Industry 4.0 Systems Integrator — Flexware Innovation

September 7, 2022
NEW YORK and TOKYO, Sep 7, 2022 - (JCN Newswire via SEAPRWire.com) - Hitachi, Ltd. (TSE: 6501) today announced that on August 31, 2022 it acquired Flexware Innovation, Inc. which has been a leading manufacturing Systems Integrator (SI) since 1996. Flexware Innovation was a strategic acquisition for Hitachi due to its focus on the TOTAL SEAMLESS SOLUTION(1) that links "shop floor" and "top floor" with data and digital technology.Business strategy in the industry field centered on North America, including Flexware Innovation, Inc.With this acquisition of Flexware Innovation, Hitachi will strengthen and enhance its business in the domain of MES (Manufacturing Execution Systems), SCADA (Supervisory Control and Data Acquisition), Software Development, Business Intelligence (BI), and ERP (Enterprise Resource Planning) implementation capabilities in North America, and accelerate the digitalization with JR Automation(2) which engages in the robotic SI & automation. Further, through cooperation with Hitachi Vantara which has expertise in building and deploying Enterprise and Cloud applications*5, Hitachi will be able to provide TOTAL SEAMLESS SOLUTION from robotic SI & automation, MES, SCADA, BI, and ERP and help manufacturing leaders increase corporate value.Background & Business StrategyHitachi's basic approach for the industry field is to globally develop TOTAL SEAMLESS SOLUTION that solves issues existing in the boundaries between shop floor, top floor and supply chain to create new business value, by taking advantage of having offerings ranging from products, OT (Operational Technology) and IT (Information Technology) systems integration capabilities.Above all, it is expected that North America will continue to experience high growth and North America will continue to adopt advanced digital technologies, so Hitachi has positioned North America as a key market. In 2017, Hitachi acquired Sullair(3), which engages in the air compressor business, and it acquired JR Automation in 2019. Further, Hitachi formed Hitachi Industrial Holdings Americas(4) in 2020 to strengthen integrated business operations of industry field in the region. Under the Hitachi Industrial Holdings Americas leadership are Sullair, JR Automation, and Flexware Innovation, the newly acquired company. The global pandemic and resulting supply-chain challenges have caused a continued need for quality and productivity improvements across all industry sectors. Hitachi is uniquely positioned to provide TOTAL SEAMLESS SOLUTION by taking advantage of their global platforms such as Lumada(5) coupled with the strength of JR Automation and Flexware Innovation in the IT/OT space.The Strategy Behind the Flexware Innovation AcquisitionMany technical firms focused on the manufacturing and industrial sectors are solely focused on a particular industry or are limited to the controls or machinery layer. Flexware Innovation is unique because they focused on the Manufacturing Execution Systems space beginning in 1996 and have proven that they can add value to their enterprise clients in many vertical industries such as Life Sciences, Food & Beverage, Utilities, Metal and Steel, and Automotive and Discrete manufacturing. Their capabilities range from controls engineering and safety assessments all the way up to ERP implementation. Having developed or implemented many complex enterprise MES solutions, Hitachi plans to leverage Flexware Innovation's expertise to compliment the capabilities of JR Automation, and Hitachi Vantara. Hitachi realizes that the North American market is a prime area for growth and is passionate about adding business value to its clients. This synergy with Flexware Innovation's history made this partnership an obvious choice. It is important to note that Hitachi plans to support and grow Flexware Innovation's current customer base which includes notable global brands."I am very happy to have Flexware Innovation as a new family member of the Hitachi Group. Moving forward, we will strive to solve customers' challenges and maximize their corporate value in North America through the combination of Hitachi's products, OT, IT, and Lumada which utilizes advanced digital technologies, the SI technologies and development capabilities of Flexware Innovation, the robotic SI & automation of JR Automation, and other resources," said Kazunobu Morita, Vice President and Executive Officer, CEO of the Industrial Digital Business Unit, Hitachi, Ltd."Our people are passionate about solving problems for our customers. This new partnership with Hitachi will allow us to do that on a larger stage, with strong vision and backing from a respected global technology company. We have developed a unique culture at Flexware Innovation that merges perfectly with Hitachi's Founding Spirit. I am genuinely excited for our future together," - Scott Whitlock, Founder and President & CEO of Flexware Innovation.Whitlock will remain as President & CEO of Flexware Innovation in partnership with the leaders of Hitachi Industrial Holdings Americas.(1)TOTAL SEAMLESS SOLUTION is a registered trademark of Hitachi, Ltd. in Japan and US.(2) Hitachi, Ltd. news release titled "Hitachi Agrees to Acquire JR Automation, a Robotic System Integrator in the U.S." announced on April 24, 2019.(3) Hitachi, Ltd. news release titled "Notice of Determination of Transfer Execution Date Associated with Acquisition of U.S.-based Air Compressor Manufacturer, announced on July 6, 2017.(4) Hitachi, Ltd. news release titled "Hitachi Announces Establishment of Hitachi Industrial Holdings Americas, Inc. to Strengthen the Industry Business in North America" announced on April 1, 2020 (5) Lumada: A collective term for solutions, services and technologies using Hitachi's advanced digital technologies to generate value from customer data and accelerate digital innovationAbout Hitachi, Ltd.Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company's consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema ACN Newswire

Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema

September 6, 2022
LAUSANNE, Switzerland, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - Oculis S.A., ('Oculis') a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, announces that the Phase 2 DX-211, a randomized, double blinded, multi-center and vehicle controlled clinical trial assessing the safety and efficacy of topical OCS-01 in patients with Diabetic Macular Edema (DME) (NCT05343156) has been published by the Acta Ophthalmologica journal. The publication is accessible on the National Institutes of Health (NIH) website here ( https://pubmed.ncbi.nlm.nih.gov/35848336/ ). In addition, a new subgroup analysis of this study was also recently presented by Pr R. Tadayoni at the 22nd EURETINA Congress on 2nd September in Hamburg, Germany.-- Positive Phase 2 data, published in journal ACTA, provides the first proof-of-concept for a topical drug effect in diabetic macular edema (DME) -- Dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol-- Subgroup analysis, presented by Pr Ramin Tadayoni at EURETINA, suggests even greater improvement in patients with lower baseline visual acuity-- If approved, OCS-01 has the potential to provide a new and potentially the FIRST non-invasive eye drop option for DME patientsThe dataset published shows OCS-01 to be superior to vehicle in the primary efficacy analysis of BCVA change from baseline with a between group difference of +1.58 ETDRS letters at the pre-specified significance level of 0.15. Mean CMT showed a statistically significant greater decrease from baseline in the OCS-01 group compared to vehicle at all post-baseline time points up to and including Week 12 (-54micrometer OCS-01 vs. -17micrometer vehicle) and reversed towards baseline when treatment stopped at 12 weeks, demonstrating the pharmacological effect of OCS-01 on retinal edema. OCS-01 was well tolerated and no significant or unanticipated ocular adverse events were observed.Subgroup analysis in patients with BCVA baseline is less than or equal to 65 letters, presented at EURETINA 2022, showed greater improvements in both CMT (-77.4micrometer OCS-01 vs. -23.1micrometer vehicle) and BCVA (+2.9 ETDRS letters in OCS-01 vs vehicle) at week 12.Approximately 37 million people are affected by DME worldwide, representing around 7% of the large and growing diabetes patient population. DME is the build-up of fluid (edema) in the macula (the macula is important for the sharp, straight-ahead vision that is used for reading, recognizing faces, and driving). DME is the most common cause of vision loss among people with diabetic retinopathy and a leading cause of new cases of blindness in US adults. Although treatment options currently exist, all of them are invasive (injections or implants) and represent a significant burden for patients and caregivers. OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone that has the potential to be the first topical eye drop and non-invasive treatment for DME. OCS-01 opens up the possibility of treating DME patients at all stages of disease with an eye drop. In addition, OCS-01 could increase the accessibility to treatment of those patients without easy access to specialists; together, this could significantly reduce the burden to the health care system and improve patient outcomes and quality of life.OCS-01 is currently under investigation for the treatment of DME in the ongoing Phase 3 DIAMOND trial to confirm these findings in a larger patient population. Riad Sherif, M.D., CEO of Oculis, said: "We are delighted by these data from the Phase 2 DX-211 study, which further reinforce the potential of OCS-01 to provide patients with a potentially transformative treatment of DME as the first non-invasive, eye drop, option. An effective topical treatment for DME could expand the proportion of patients treated, especially those with recent onset DME, as well as provide a treatment option to general ophthalmologists prior to referral to a retina specialist and thereby, improving access to treatment. We look forward to the results of the ongoing Phase 3 DIAMOND trial as Oculis seeks to deliver life-changing treatments that can be accessed globally for the world's most prevalent ocular diseases." Pr Ramin Tadayoni, MD, PhD, Professor of Ophthalmology at Universite de Paris, said: "The development of effective topical eye drops for posterior segment disorders such as DME would offer easier, non-invasive options than those currently available, and could be widely adopted across all socioeconomic and geographic boundaries. This would allow earlier treatment in DME, reduce the burden on both patients and their caregivers with potentially less injections per year if combined with current standard of care, increase adherence and ultimately, improve outcomes worldwide. OCS-01 is the most developed and promising topical therapy for DME to date, and I look forward to its further development as a potentially transformative treatment for patients in need."About OculisOculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs with breakthrough innovations. Oculis's highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide. Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.For more information, please visit: www.oculis.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

ApexBrasil Agency and Alibaba Signed a Memorandum of Understanding

September 6, 2022
HONG KONG, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - The Brazilian Export and Investment Promotion Agency (ApexBrasil) held a memorandum of understanding (MoU) signing ceremony with Alibaba Group to deepen their cooperation on cross-border e-commerce platforms during the China International Fair for Trade in Services on September 3, 2022. Under the framework of the MoU, the two parties will expand cooperation and strengthen Brazilian enterprises' e-commerce, cross-border trade and digitalization, thus accelerating the deepening of digital cross-border trade, and creating more opportunities for Brazilian products to be exported to Asian and global markets through e-commerce.Under the framework of the MoU, the "Made in Brazil" national pavilion will be launched on Alibaba's international website. 100 local companies with e-commerce experience in the platform's hottest-selling industries will join "Made in Brazil" label, many of them receiving settlement support and subsidies from ApexBrasil. Alibaba.com provides exclusive services for operations as well as B2B distribution services for customized Brazilian exports. In addition, in order to cultivate Brazil's digital economy talents and support the development of the local e-commerce ecosystem, ApexBrasil and Alibaba agreed to jointly promote a digital economy training program in Brazil to educate Brazilian entrepreneurs as well as professionals and students in digital trade and relevant fields and provide a solid foundation for the industry's future development.In 2021, Brazil's e-commerce sales increased by 35%. Brazilian companies' sales in China through Alibaba's e-commerce platform are projected to reach US$ 253 million, with food products particularly in high demand by Chinese consumers. ApexBrasil has established close cooperation with Alibaba. In addition to promoting Brazilian companies' global sales, ApexBrasil is also taking this opportunity to enhance Brazilian companies' understanding of the Chinese market and its opportunities, hence deepening their cooperation with Alibaba's retail channels. With continuous support, ApexBrasil is accelerating the digitalization and globalization of Brazilian SMEs and Brazilian companies are enthusiastic about joining Alibaba's e-commerce platforms. Since 2021, ApexBrasil has reached 370 Brazilian companies interested in selling through Alibaba.com with the Acceleration program in Digital Platforms.The expanding cooperation between ApexBrasil and Alibaba over the years has carried out fruitful results. Since June this year, Brazilian companies and Alibaba successfully promoted the intention of 2 key companies to export their products to China, Brazilian specialty coffee SANTA MONIKA, a well-known Brazilian brand, and the juice brand NATURAL ONE. The signing and approval of the two contracts are expected to be completed in September with the first order placed in October. They will cooperate with Alibaba Group's hybrid (online and offline) platform to introduce Brazil's high-quality products to the Chinese market.Lucas Fiuza, Business Director of ApexBrasil said: "ApexBrasil has been working diligently to promote international e-commerce so that Brazilian companies can expand their export options to include e-commerce. Specifically, I would like to highlight the successful projects we have started with Alibaba.com so that more Brazilian companies can learn how to use this international platform for selling their products. I would also like to send a special message to all companies who are following us. Brazil is the right place for your business, and ApexBrasil is how you find the best deals. Think Big, Think Brazil." Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022 JCN Newswire

Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022

September 6, 2022
TOKYO, Sep 6, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13. A late-breaking oral presentation of detailed results from the LEAP (LEnvatinib And Pembrolizumab) clinical program including the final analysis of the Phase 3 LEAP-002 trial will be featured in a Proffered Paper session (NCT03713593; Presentation: #LBA34). The study evaluated the combination of lenvatinib plus anti-PD-1 antibody pembrolizumab from Merck & Co., Inc., Rahway, NJ, USA versus lenvatinib monotherapy as a first-line treatment for patients with unresectable hepatocellular carcinoma. Additionally, two mini-oral presentations will feature updated efficacy and safety data from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial evaluating the combination in patients with advanced renal cell carcinoma (NCT02811861; Presentation: #1449MO) and Phase 3 Study 309/KEYNOTE-775 trial evaluating the combination in patients with advanced endometrial carcinoma (NCT03517449; Presentation: #525MO). In addition, a new post-hoc analysis of three pivotal Phase 3 studies (Study 301/NCT00337103, Study 304/NCT02225470 and the EMBRACE trial/Study 305/NCT00388726) evaluating the efficacy of eribulin (HALAVEN) versus other chemotherapies (capecitabine, vinorelbine and Treatment of Physician's Choice [TPC], respectively) in patients living with metastatic breast cancer whose tumors have low or no HER2-expression will be presented during a poster session (Presentation: #259P). "We look forward to presenting data at ESMO, showcasing Eisai's latest research on both lenvatinib and eribulin, with the goal of continuing to help people living with various types of cancer," said Dr. Takashi Owa, Chief Scientific Officer, Deep Human Biology Learning, Senior Vice President, Eisai Co., Ltd. "Presentations on the LEAP clinical program as well as new analyses for eribulin reinforce our commitment to the ongoing research of our portfolio in an effort to better serve patients and healthcare providers." In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with pembrolizumab. To date, more than 15 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types. This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.For more information, visit www.eisai.com/news/2022/news202265.html. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs ACN Newswire

Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs

September 6, 2022
SYDNEY, AU, Sep 6, 2022 - (ACN Newswire via SEAPRWire.com) - Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside Company for their global expansion program.Watch the video here: https://www.avancecro.com/avance-clinical-north-america-operations/Avance Clinical is the largest and most established full-service Australian and New Zealand CRO with a proven track-record of data acceptance by the FDA and all other major regulatory bodies.The combined Avance Clinical Australia, New Zealand, and North American operations deliver a unique GlobalReady drug development model for biotechs.Avance Clinical's CEO Yvonne Lungershausen said: "Avance Clinical has been working with C3 Research Associates in recent years and they share a similar culture and focus on customer service and clinical excellence. This strong relationship made C3 Research Associates a natural acquisition choice for Avance Clinical's expansion plans into North America. The due diligence process has taken more than 6 months and we are excited to now welcome our US team and offer the GlobalReady model for our clients. "This acquisition gives our biotech clients conducting their early phase studies in Australia and New Zealand a seamless journey into the US to continue their clinical development programs, retaining the same high-quality CRO, which reduces time and cost and delivers quality FDA-accepted data. This GlobalReady model is designed to extend biotechs' investments so they can achieve greater clinical development milestones with reduced spend, all with the assurance of FDA accepted data. "In addition, the attractive 43.5% rebate on clinical spend in Australia, offers our clients the opportunity to utilize our North American operations expertise and team, whilst maintaining services in Australia to maximise their rebate potential. "We often point to the fact that there are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which again demonstrates Australian data acceptability with the FDA and other major regulatory authorities."We will be making significant investments in our US operations including growing the team to more than 120 people and leveraging their deep industry experience across a broad range of therapeutic areas, in particular oncology.Clients can be assured the world-class best practice technologies, systems and processes will be integrated across all regions."This seamless GlobalReady journey is designed for success whereby biotechs can:- Take advantage of the Australian early phase clinical trial landscape (No IND and 43.5% tax rebate)- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)- Seamlessly operationalise global dose-escalation and dose-expansion trials across the two regions- Harness significant speed and cost advantages- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities The Avance Clinical team offers exceptional study approval and success rates which can be attributed to its deep scientific expertise, advanced data technologies, knowledge of the Australian, New Zealand and North American regulatory environment, and its extensive relationships with sites and KOLs.The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which allows it to manage pre-clinical and clinical trials for vaccines and GMO therapies.Avance Clinical's has achieved high growth and industry-leading repeat business rates with its focus on gold standard technology paired with solution-orientated clinical experts. This is the mix that biopharma clients clearly require in this fast-moving, competitive and high-stakes sector.Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.Learn about the Australian Advantage here: https://www.avancecro.com/the-australian-advantage/Meet the North American leadership team here: https://www.avancecro.com/avance-clinical-north-america-operations/For more information about the benefits of running your next study with Avance Clinical contact us https://www.avancecro.com/contact-us/About Avance ClinicalAvance Clinical is the largest premium full-service Australian CRO with operations across Australia, New Zealand and North America delivering quality clinical trials with globally accepted data for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.Frost & Sullivan AwardsAvance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.Pre-clinical to Later Phase Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to later phase clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.State-of-the-art TechnologyAvance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM and Medrio are just some of the technology partners.Media Contacts: Avance ClinicalChris Thompsonmedia@avancecro.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
DECOMAN from Hong Kong Utilizes Technologies to Go Global, Two More Markets in the APAC Region this year ACN Newswire

DECOMAN from Hong Kong Utilizes Technologies to Go Global, Two More Markets in the APAC Region this year

September 5, 2022
SEOUL, SOUTH KOREA, Sep 5, 2022 - (ACN Newswire via SEAPRWire.com) - HK DECOMAN Technology Limited ("DECOMAN") is now expanding its footprint in Korea to capture the opportunities of growing demand for its services. With the Taiwan expansion begun in January, this is the second APAC market DECOMAN entered in 2022.Coworking space at the KSGC campusCoworking office shared between talented entrepreneurs and promising startups selected by KSGCPen Ventures and DECOMAN in KoreaRecognized by Korean Government's Accelerator ProgramOut of 2,653 companies applying from 122 countries, DECOMAN is among the top 54 startups this year selected by K-Startup Grand Challenge ("KSGC"), a global startup accelerator program organized and financed by the Korean government, to enhance the local entrepreneurship ecosystem. As a KSGC participant, DECOMAN team has been utilizing the facilities and coworking spaces at the KSGC campus in Pangyo Techno Valley - a technology hub near Seoul, to build its K-network and foundation.Support from International VC FirmIn addition to the guidance and opportunities that DECOMAN can gain from KSGC, California venture capital firm Pen Ventures also sails along the journey (read coverage here https://www.fnnews.com/news/202208160811387147 ) with DECOMAN by being its mentor and sharing its extensive network. In the coming months, DECOMAN will make solid progress in respect of its planned road map.Proven Success in Taiwan ExpansionEarlier this year, DECOMAN has already entered Taiwan and debuted on the stage of SparkLabs Taipei DemoDay 6 (read coverage here https://meet-global.bnext.com.tw/articles/view/47581 ), kicking off its operation there and bringing innovation to the renovation market.Expand despite the PandemicIn 2021, DECOMAN received investments from international startup accelerator SparkLabs Taipei, and was invited to participate in SparkLabs Taipei DemoDay 6 in January 2022. DECOMAN has since been in discussion with several local investors to prepare for the next stages. As of now, the renovation-design matching service and "Deco Academy" courses have already been introduced to the locals. Notwithstanding the impacts of the pandemic, DECOMAN has made a strong foundation in Taiwan by recruiting Taiwanese staff to enable rapid executions adaptable to local lifestyles as well as concrete social media presence for content sharing.About DECOMANDECOMAN is a fast-growing one-stop O2O renovation platform, aiming to disrupt the traditional renovation industry by bringing standardization, transparency, convenience and automation to the industry. DECOMAN does it all. With DECOMAN, homeowners no longer need to rely on risky and primitive ways to ascertain a company's credibility and quality of service, nor do they need to worry about mastering a wide range of knowledge for a one-time project. DECOMAN has been backed by large players in the property industry and is currently valued at US$27M. (Visit our websites to know more - Hong Kong https://hkdecoman.com/; Singapore https://www.sgdecoman.com/; Taiwan https://twdecoman.com/; Macau https://modecoman.com/; Korea https://krdecoman.com/ko/)For media enquiries, please contactPinky Hui at pinky_hui@hkdecoman.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Leading VC Firm, Black3Lab Capital Announces Investment in Ripe Web 3.0 Sectors SeaPRwire

Leading VC Firm, Black3Lab Capital Announces Investment in Ripe Web 3.0 Sectors

September 2, 2022
New York, NY, September 02, 2022 – (SEAPRWire) – Black3Lab Capital, a venture capital firm built to empower web 3.0 companies with potential for global mass adoption, has announced investments in ripe web 3.0 sectors. Black3Lab’s proposed $50 to $100 million fund will focus on building a genuinely feasible economy of web 3.0-fueled products and services for the global populace. In addition to investing in potentially productive web 3.0 sectors, Black3Lab will undertake the enterprise adoption of social media, gaming, and NFTs. At a recently concluded launch ceremony, co-founder of Black3Lab, Alex Chong, announced that the putative investment fund is in partnership with three famous partners. The Black3Lab fund will focus primarily on enriching projects with the potential to accelerate global adoption. “We are hyper-focused on web 3.0 companies with the suitable DNA to integrate with existing conglomerates with millions of customers for Black3Lab portfolio companies to tap. Ultimately, mass user adoption will allow web 3.0 platforms and projects to achieve explosive growth and sustainable revenue generation capabilities,” Alex Chong reveals. Unlike web 2.0, which gave rise to internet giants like Google, Apple, Facebook, etc., web 3.0 promotes user-centric ownership, harmonizing perfectly with human incentives. Speaking about the current web 2.0 internet phase and the rise of centralized tech giants, the co-founder of Black3Lab reiterated Alex Chong’s claims of web 3.0’s potential to deliver at least ten times the market opportunities of the former. “User-centric networks deliver significantly higher and more explosive growth than their centralized competitors. At the core, you can always find more favorable terms for users. Web 2.0 gave birth to a US$10 trillion market, and now web 3.0 has the potential to deliver ten times the market opportunities,” Candy states. The Black3Lab fund will incorporate a dynamic trading strategy that delivers consistent returns of over 30% to investors. Black3Lab Partners Per Alex Chong’s announcement at the launch ceremony held at the Peninsula Hotel, Hong Kong, on 18th August 2022, Black3Lab has partnered with notable media veterans like Bob. Bob led the global collaboration team of some of the biggest media tech companies. He also led Strategies and Partnerships at Forkast—a web 3.0 media ecosystem. Bob recapitulates Candy’s idea of user-centric ownership as the key to driving mass adoption in the emerging web 3.0 space. “Black3Lab Capital is notably unique: We exist not just out of the goal for strong financial returns but to foster the mass adoption of web 3.0 solutions. We believe user-centric ownership will be the key to unleashing the next-generation internet,” Bob says. About Black3Lab Capital Black3Lab Capital is a VC firm founded in Hong Kong. Black3Lab aims to empower web 3.0 companies with maximum potential for accelerated mass success, offering high returns to investors. The team comprises renowned enterprise founders, tech developers, VCs, media executives, and F&B entrepreneurs keen on introducing a more equitable, rewarding, and innovative internet economy. Social Contact Instagram: https://www.instagram.com/black3lab/ Media Contact Brand: Black3Lab Capital Contact: Alex Chong, Co-founder & Partner Email: info@black3lab.com Website: https://www.black3lab.com/ PR provider: https://finpr.agency SOURCE: Black3Lab Capital The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
BoB Financial and Snapdeal Launch Co-Branded JCB RuPay Contactless Credit Card ACN Newswire

BoB Financial and Snapdeal Launch Co-Branded JCB RuPay Contactless Credit Card

September 2, 2022
MUMBAI, INDIA, Sep 2, 2022 - (ACN Newswire via SEAPRWire.com) - BOB Financial Solutions Limited (BFSL), the wholly-owned subsidiary of Bank of Baroda (BoB) and Snapdeal in partnership with National Payments Corporation of India (NPCI) and JCB International Co. Ltd. have announced the launch of the Snapdeal BoB JCB RuPay Credit Card. The card is designed keeping in mind the purchase behaviour of shopping enthusiasts and will offer a host of attractive benefits and rewards. The card will also be usable at international merchants and ATMs through the extensive JCB global network.Users of the co-branded credit card will receive up to 5% unlimited cashback (accrued as 20 reward points on every INR 100 spent) on the Snapdeal app and website. Activation of the co-branded credit card within 30 days of issuance will entitle the cardholder to shopping benefits on Snapdeal worth up to INR 500.The card also offers 10 reward points per INR 100 spent on online, grocery and departmental store spends. For purchases in all other categories, customers will get 4 reward points for every INR 100 spent. The cardholders will also enjoy free Add-On cards for family members, waiver of 1% fuel surcharge, easy EMI options (pre and post purchase), and periodic offers across merchants.Commenting on the partnership, Shailendra Singh, MD & CEO, BOB Financial said, "We are happy to launch our co-branded credit card with Snapdeal, in partnership with NPCI, at a time when both new customer acquisition as well as usage from smaller cities and towns continue to grow at an impressive pace. The challenges brought about by the pandemic have resulted in a rapid adoption of digital payments even in interior locations of the country. Our co-branded credit card will offer additional value to this large segment of customers that constitute Bharat!".Himanshu Chakrawarti, President, Snapdeal Limited said, "Snapdeal's target audience is the value-savvy, mid-income, price-conscious buyers who predominantly live in the smaller cities of India. The partnership between BOB Financial, NPCI and Snapdeal brings together parties with a deep understanding of this mega-segment of consumers and how they are evolving in terms of their use of technology and digital payments. Our co-branded card is another important step in offering additional value to our users."Ms. Praveena Rai, COO, NPCI said, "We are happy to associate with BOB Financial and Snapdeal for the launch of the distinctive co-branded JCB RuPay Contactless Credit Card. We believe that this proposition will appeal strongly to millions of Snapdeal and BOB Financial's customers at large by offering them a unique and rewarding experience. At NPCI, we are strategically focussing on creating a wide array of offerings in the credit segment for the customers to experience delightful and memorable retail as well as e-commerce shopping."Mr. Yoshiki Kaneko, President and COO, JCB International Co. Ltd. said, "We are extremely excited to partner with BFSL and Snapdeal through our esteemed network partner RuPay. This product, besides offering great value and benefits within India, comes with unique benefits and privileges internationally. This includes access to exclusive JCB in-city lounges at many key international travel destinations and special discounts exclusively for JCB cardmembers at many international merchants. We are sure the cardmembers will enjoy the benefits of carrying this card with them wherever they go."About BOB Financial Solutions LimitedBOB Financial Solutions Limited was established in the year 1994. It is a Non-Banking Financial Company, wholly owned by Bank of Baroda. The Company's primary business is in credit cards with its key differentiator being simple, easy-to-understand products that are fairly priced and efficiently serviced. A pioneer in the space of credit cards, BOB Financial offers an array of products catering to all segments of customers. It is leveraging state-of-the-art technology to provide unique payment solutions to its customers. For more information, visit www.bobfinancial.comMedia contact for BFSL:Ashutosh Kumar9811174731ashutosh.kumar@bobfinancial.comAbout SnapdealSnapdeal is one of India's best known e-commerce companies and has an exclusive focus on the value segment with more than 90% of the products on its platform priced under Rs. 1,000. Snapdeal as a brand is synonymous with value e-commerce: good quality, trendy and affordably priced products that fulfill the aspirational needs of value-conscious buyers. Over the last several years, the company has enhanced its expertise in catering to the value segment of the Indian e- commerce market, comprising mid-income users who have a budget-led approach to spending and access the Internet primarily through their mobile phones. Snapdeal receives more than 86% of its orders from outside metro cities, with more than 72% of its orders coming from buyers living in Tier 2+ cities & towns. It covers 96.65% of India's pin codes and has served buyers from more than 2,500 cities. Founded in 2007 as a coupon booklet business, it transformed itself into an e-commerce deals platform in 2010. Subsequently, it launched the Snapdeal e-commerce marketplace in 2012.About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. JCB issues cards across various countries and regions internationally with more than 140 million cardmembers. JCB Cards are accepted at tens of millions of merchants globally through its vast acceptance network. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/enMedia contact for JCBAyaka NakajimaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@jcb.co.jpAbout NPCINational Payments Corporation of India (NPCI) was incorporated in 2008 as an umbrella organization for operating retail payments and settlement systems in India. NPCI has created a robust payment and settlement infrastructure in the country. It has changed the way payments are made in India through a bouquet of retail payment products such as RuPay card, Immediate Payment Service (IMPS), Unified Payments Interface (UPI), Bharat Interface for Money (BHIM), BHIM Aadhaar, National Electronic Toll Collection (NETC Fastag) and Bharat BillPay. NPCI is focused on bringing innovations in the retail payment systems through the use of technology and is relentlessly working to transform India into a digital economy. It is facilitating secure payments solutions with nationwide accessibility at minimal cost in furtherance of India's aspiration to be a fully digital society. For more information, visit: https://www.npci.org.in/Media contact: Shruti Singh9654497747shruti.singh@npci.org.inPriyanka Chavda9619378489priyanka.chavda@npci.org.inAdfactors PRBanali Banerjee/Pragya Sahay9769610385/7982347652banali.banerjee@adfactorspr.com / pragya.sahay@adfactorspr.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
aCommerce and Johnson & Johnson Launch Sustainable Packaging Solution for a Better E-commerce Future in the Philippines ACN Newswire

aCommerce and Johnson & Johnson Launch Sustainable Packaging Solution for a Better E-commerce Future in the Philippines

September 1, 2022
BANGKOK & MANILA, Sep 1, 2022 - (ACN Newswire via SEAPRWire.com) - aCommerce Group, the largest end-to-end e-commerce enabler in Southeast Asia, has partnered with Johnson & Johnson Philippines, part of the largest and most broadly based healthcare company in the world, in a joint venture to offer a sustainable packaging alternative and 100% recyclable solution in the Philippines.The solution was developed through a wide-scale collaboration to reduce e-commerce waste and create a sustainable future for e-commerce in Southeast Asia. The forecasted amount of plastic savings from this initiative would be equal to 106,684 SQM of plastic - the equivalent to the area of 254 basketball courts. The new packaging solution will replace previously non-recyclable packaging materials with new, innovative, green, and simple packaging, rolling out through the month of August.The paper used in the new packaging is 100% recyclable, non-toxic, and biodegradable. The innovative VoidFill acts as a box filler, replacing the plastic bubble wrap, and offers superior protection from damages by filling any excess space in the box. An additional cushioning layer is added to fragile deliveries to ensure outstanding control against shock and vibrations. The final layer, the Geami WrapPak layer, is added to avoid any surface abrasions, minor handling damages, and internal impact.Both companies' sustainability goals are naturally aligned. "As part of our responsibility to the environment. aCommerce will continue to invest in a sustainable future. We are excited to offer recyclable and biodegradable solutions using cutting-edge material engineering. We are truly fortunate to have like-minded partners such as Johnson & Johnson, that take action in order to create a cleaner future," said Paul Srivorakul, Group Chief Executive Officer at aCommerce."We are committed to doing our part to leave a better world for future generations. We are excited to pilot our green e-commerce initiative with Shopee and Lazada, knowing that this 'first step' will help reduce plastic pollution that goes into our landfills and into our waterways. We hope that our consumers will take advantage of the offer when they order their favorite Johnson & Johnson products through Shopee and Lazada. Our consumers win, and so will our environment," said Denise Peralta, Johnson & Johnson Philippines head of e-commerce.Visit Johnson & Johnson stores and shop responsibly and worry-free:Shopee: https://shopee.ph/johnsonandjohnson.phLazada: https://www.lazada.com.ph/shop/johnson-johnsonReleased for aCommerce Group by MT Multimedia Co LtdWasana Wongsiri (Jiab), T: +66 84 359 0659, E: wasana.w@mtmultimedia.comJohnson & Johnson (Philippines), Inc. (J&J Philippines) launched J&J PH Chat & Shop as its official social-commerce platform to simplify purchasing of various consumer health products. Powered by aCommerce, it delivers a fully-automated experience - 24/7 shopping via Chatbot with a live agent ready to assist customers during business hours, and seamless, easy navigation even for new users. https://facebook.com/jnjphchatshop.aCommerce (SET: ACOM) revolutionized e-commerce enablement with a cutting-edge platform & technology stack, EcommerceIQ. Proprietary software includes innovative omnichannel management software. We drive brands to achieve e-commerce goals with high-performance digital marketing, online store development & management, data & analytics, customer care, fulfillment, & delivery services. Visit https://acommerce.asia. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Cyberarrow and G42 Cloud Announce New Partnership SeaPRwire

Cyberarrow and G42 Cloud Announce New Partnership

September 1, 2022
Dubai, UAE, September 01, 2022 – (SEAPRWire) – Innovative cyber security provider, CyberArrow, is excited to be expanding its footprint within the MENA region after signing a new Memorandum of Understanding with pioneering AI and Cloud Computing organization G42 Cloud to host and support delivery of their services. G42 Cloud is a subsidiary of leading AI and cloud computing provider G42, and its powerful cloud and market presence have helped CyberArrow to continue to scale its operation and reach more customers across MENA by becoming one of the ecosystem partners that can be hosted and deployed to customers on G42 Cloud. CyberArrow works with organizations of all sizes, supporting them to enhance their cyber security resilience and posture. By acquiring the CyberArrow GRC solution, businesses of all sizes can now save thousands of hours on cyber security GRC tasks while ensuring full compliance with international- and local standards. The new agreement will allow for the automation of a wide array of Governance, Risk Management, and Compliance (GRC) tasks, helping both the government and those working within private entities to become more secure. This is a vital step in boosting the overall cyber security within organizations across the MENA region. Amar Basic, Co-Founder of CyberArrow, said, “We are excited to be working with G42 Cloud. Their work is well recognized in the region, and this new MoU will help us to strengthen our offering within the MENA region as well as allowing us to offer our solutions to an even larger audience. This latest partnership only serves to strengthen our mission to promote better use of internet and technology among both the current and future generations.” Talal Al Kaissi, CEO of G42 Cloud added, “We are looking forward to working with CyberArrow in order to enhance our ecosystem offerings with one of the top cyber security solutions which can now be served on our sovereign cloud to the government sector. We have always been committed to supporting our ecosystem of partners, deliver value to their customers by providing them with the very best products as well as world-class service, and this new partnership is an important step in helping to boost the cyber security products delivered using our cloud.” For more information on CyberArrow, visit https://www.cyberarrow.io For more information, visit Website: https://www.cyberarrow.io/ LinkedIn: https://www.linkedin.com/company/cyberarrow/ Media Queries Amar Basic, Co-founder Email: amar.basic@cyberarrow.io Tele: +971555712624 Addr: Address (with Postcode): Marina Plaza, office 2902, 450158, Dubai, UAE SOURCE: CyberArrow The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
Newly-established Center of Excellence hosts specialists to guide customers in seamless shift to modernized platforms JCN Newswire

Newly-established Center of Excellence hosts specialists to guide customers in seamless shift to modernized platforms

September 1, 2022
TOKYO, Sep 1, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu today announced a comprehensive update to bolster its modernization services offerings, boldly reimagining its approach for customers' existing information systems to realize their digital transformation (DX). Fujitsu will work with customers to visualize their current assets including business processes, data, applications, and IT infrastructure to design the ideal DX platform, while providing guidance in streamlining and modernizing systems.Figure 1: Strengthening ModernizationFigure 2: Process of modernizationTo launch this effort, Fujitsu is establishing a new center of excellence (CoE), the Modernization Knowledge Center, which will serve as a focal point for technical information and expertise essential for modernization. This center will begin offering support for customers in the Japan market from September 2022, with global service support to follow.With this move, Fujitsu demonstrates its commitment to delivering an optimal experience for customers with a comprehensive suite of modernization services, encompassing robust specialist support, bolstered by leading-edge technologies to help guide customers on their modernization journeys with confidence and peace of mind.Resilience and agility in information systems for an unpredictable eraAs companies continue to grapple with an increasingly challenging and unpredictable world, the pressure to adapt to changes with agility and resilience grows more intense along with the need to preserve business competitiveness and achieve sustainable management. Traditionally, information systems have been built for the public and financial sectors and for the separate operations that comprise a company's business activities, like production, distribution, sales, and accounting. In many cases, the lack of uniformity in techniques for building systems and data structures means that migration to modern systems can become time consuming, costly, and disruptive to businesses.Fujitsu has been working with customers to modernize legacy systems to overcome the "2025 Cliff" revealed by Japan's Ministry of Economy, Trade and Industry's DX Report.Fujitsu announced end of life and end of maintenance dates for mainframe and UNIX servers (1) as part of its Hybrid IT roadmap in February 2022. To guide its mainframe and UNIX server customers as they navigate the modernization of their systems, Fujitsu draws on end-to-end specialist expertise as well as its world-class technological capabilities in key areas including Computing, Networks, AI, Data & Security, and Converging Technologies to deliver robust, comprehensive modernization services.Fujitsu anticipates that 3,000 customers globally will use its Modernization Services, with 35,000 people engaged with delivering these capabilities, drawing from resources including Fujitsu's network of Global Delivery Centers by fiscal 2025.Strengthening modernization servicesFujitsu's modernization services consist of four key elements: (1) Business and asset visualization; (2) Grand design; (3) Comprehensive information system streamlining; and (4) Modernization. Fujitsu also provides technical assistance for customers who wish to modernize on their own.(1) Visualization of operations and assetsFujitsu leverages a range of process mining tools including "Celonis EMS" (2) and "SAP Signavio" (3) to visualize business processes, inventory master data, data through data analytics, and applications.For application visualization, Fujitsu will conduct structural analysis of applications, working asset analysis, similarity analysis, asset characteristic analysis, and system correlation analysis using its software map (4).(2) Grand DesignIn collaboration with Ridgelinez Ltd. (5) and consulting partners, Fujitsu will create a grand design using frameworks such as the TOGAF Standard (6), a standard of The Open Group, which is one of the methodologies for EA (Enterprise Architecture) (7).(3) Comprehensive information system streamlineSome information system assets are maintained and operated even though they are rarely used. Through visualization, Fujitsu can help customers strategically streamline operating systems assets.(4) ModernizationFujitsu will help modernize and systems by rehosting, rebuilding, conducting service migration, as well as leveraging a variety of tools for rewriting (including "PROGRESSION" (8)) along with other appropriate measures according to individual information system parameters within customers' assets. For IT infrastructure, Fujitsu will support the transition to public cloud and private cloud based on Fujitsu Uvance Hybrid IT offerings.Establishment of new CoE: "the Modernization Knowledge Center"The Modernization Knowledge Center was newly established on September 1st and will serve as a nexus for the collection of technical information and expertise related to modernization. The CoE offers customers access to resources essential to the modernization process, including technical information on mainframe UNIX server open systems, cross-enterprise and cross-industry migration best practices and experience, as well as other information on useful tools, services, and specialized partners.The CoE will draws on a full suite of capabilities and resources, to offer customers support including: (1) collection and organization of internal and external knowledge, (2) promoting information sharing, (3) collaboration with specialized partners that provide various tools and services, (4) providing support for business deals and technical matters, (5) providing feedback on knowledge gained through delivery practices, and (6) insights into the status of modernization of customer systems.(1) End of sales and end of maintenance for mainframe and UNIX servers: Sales of mainframes will end in FY2030 and maintenance will end in FY2035. Sales of UNIX servers will end in FY2029 and maintenance will end in FY2034.(2) "Celonis EMS": Celonis Execution Management System is a solution platform with process mining technology provided by Celonis SE, a cloud software vendor headquartered in Munich, Germany and New York, USA.[3) "SAP Signavio": The product brand name for the process management solution provided by SAP SE.(4) Software map: A mining technology that automatically discovers functional components that implement functions and roles for business, and a tool that visualizes the entire application based on the discovered functional components as a map, available for domestic users in the Japan market.(5) Ridgelinez Ltd.: Head Office: Chiyoda-ku, Tokyo; CEO: Toshiya Imai(6) The TOGAF Standard: The TOGAF Standard, a standard of The Open Group is a proven Enterprise Architecture methodology and framework used by the world's leading organizations to improve business efficiency. The Open Group is a global consortium that enables the achievement of business objectives through technology standards.(7) Enterprise architecture: A design method to create an efficient organization by standardizing and globally optimizing the allocation of resources, business procedures, and information systems of large companies and government agencies.(8) "PROGRESSION": A rewrite solution from Fujitsu North America, Inc.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
LuckyBuy Introduces the New Solution for Acquiring Rare NFTs SeaPRwire

LuckyBuy Introduces the New Solution for Acquiring Rare NFTs

August 31, 2022
New York, NY, August 31, 2022 – (SEAPRWire) – Recently, LuckyBuy has announced the release of their new solution for acquiring rare NFTs for users. The wild world of NFTs has taken the crypto world by storm over the past 12 months, and while they are not loved by everyone, they have caught the attention of most due to the sheer number and volume of projects that have sprung up in the space focus on. However the high cost of a single NFT discourages ordinary players. In the past, the scene of harvesting high-value NFTs and Cryptos in small amounts may only exist in a dream. LuckyBuy was launched in July, 2022, where the transparency and fairness could be 100% guaranteed, allowing users to harvest high-value NFT & Crypto by participating in the “Fair hunting” at the lowest price. As the first website to make high-valued NFTs more affordable to the public, LuckyBuy is offerring a solution to increase the liquidity of NFTs and lower the threshold of NFTs without high cost. “In web2.0, people used to win the mobile phone, toys, electrical appliances and other objects they wanted with 1 dollar or even less than 1 dollar. LuckyBuy’s business model has achieved great success in web2.0. Our product R&D department is the original team of this business model. As we didn’t see anyone or any products in web 3.0, we started to think: Why not do this in web3.0 ? Why not set off a revolution in this industry? ” Santos Mario, Lead Product Designer of LuckyBuy said, “The cheapest BAYC is north of $175762, LuckyBuy provides users with oppotunities to harvest high value with 0.1/1 USDT , which lowers the threshold and enables users to win rare NFT with low cost. More innovative gameplay will be constantly launched online and a large number of precious NFTs are upcoming. So it’s quite possible that there will someone get a BAYC for only 1U at LuckyBuy in the future.” With a healthier economic model, Web3’s LuckyBuy subverts the traditional mode. The more users participate in the lottery, the more TOKEN rewards they will receive. LuckyBuy attaches great importance to the contribution of each participant to the platform, all behaviors and contributions of participants will be recorded in the form of points. Lucky Genesis Pass will be released for the first time by the end of next month, which serves as the proof of early users, enabling them to share with the empowerment of the platform. Users with Lucky Genesis Pass will have the right to vote on community proposals, exclusive welfare bonus pool, priority to experience the function, bonus points, and get more airdrops and tokens in the future. LuckyBuy announced that the fund for its investment project with giants now in place. The fund is dedicated to improving product experiences for users and providing long-term, sustainable services. The long-term sustainable development is LuckyBuy’s ultimate goal, and thus they are putting double the effort into delivering value to all of users. Stay tuned for the brand new event of the platform. About safety Winner would obtain complete NFT without worrying about the transparency. Technically speaking, there are three stages of the process: First, After all codes are sold out, data will be translated to HASH and record on the blockchain, and the Random Number 1 is the decimal numbers of the last 8 digits of the hash according to SHA256.Second, the nonce of the 10th block on the Ethereum will be obtained by the system. Random Number 2 is the decimal numbers of the last 8 digits of this nonce.Finally, calculate the Lucky code according to the vertain algorithm (details on the offical website https://luckybuy.io). About LuckyBuy LuckyBuy is a web3-commerce platform with gaming element. Backed by blockchain technology and based on Multi Chains, allowing users to gain high-value NFT & Crypto by participating in the fair “treasure hunt” event at the lowest price. Social Links Discord: https://discord.gg/syUQrngncd Telegram: https://t.me/luckybuyio Twitter: https://twitter.com/LuckyBuy_io Media Contact Brand: LuckyBuy Contact: Media Team Email: business@luckybuy.io Website: https://luckybuy.io SOURCE: LuckyBuy The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding as AcuraBio ACN Newswire

Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding as AcuraBio

August 31, 2022
BRISBANE, AUS, Aug 30, 2022 - (ACN Newswire via SEAPRWire.com) - AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, has been acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners, a global healthcare private equity firm.With more than two decades of experience, AcuraBio is a globally focussed organization bringing innovative therapeutics to market for customers in the biotech, pharmaceutical, and animal health industries. AcuraBio provides recombinant proteins and vaccines, and complex live biotherapeutic products to customers on the leading edge in emerging therapeutics. The rebranding of the company signifies an innovative new growth phase for AcuraBio. As part of the transaction, Dr. Haifer and Ampersand are bringing significant investment to the company, with a focus on expanding the organization to better serve customers. To fuel additional growth, AcuraBio is planning to increase production facility capacity, and is actively evaluating expansion into new service offerings and technological capabilities. Dr. Haifer brings a wealth of experience to AcuraBio, as the former company Chairman and investor behind Australian biotech successes such as Agilex Biolabs and Avance Clinical. "We are very excited to be reinventing a company with such deep scientific experience," said Dr. Haifer. "With our deep expertise and commitment to further investment, AcuraBio will be a leader in the APAC region for international biopharma clients attracted by the technology, scientific excellence, and innovation we will bring to the platform. I am excited to leverage Ampersand's industry expertise as we take AcuraBio to the next level." Based in the US and with more than $3 billion of assets under management, Ampersand is exclusively focused on growth-oriented investments in the healthcare sector. Ampersand has previously partnered with leading CDMOs such as Brammer Bio, ArrantaBio, Vibalogics, and Genezen, and the firm is a highly experienced investor in the emerging therapeutics CDMO industry. David Anderson, General Partner at Ampersand, said "AcuraBio is strategically positioned in Australia to support international biopharma drug development. Australia has a strong reputation for clinical and scientific excellence which is the foundation to success for a company like AcuraBio. We are extremely pleased to be working with Dr. Haifer, who is a proven biotech investor and growth strategist with a real focus on client-centric service innovations."About AcuraBioAcuraBio Pty Ltd is one of Australia's most experienced biopharmaceutical CDMOs, offering trusted, client-focused services to both domestic and international clients for the past 20 years. AcuraBio offers significant quality, cost, and IP assurances for biopharma companies around the world. World-class researchers and proven facilities, a streamlined regulatory framework, generous tax incentives, and government funding make Australia a prime location for biotech research. AcuraBio has the following operating licenses: TGA (Australian FDA equivalent) license for the manufacture of human therapeutic APIs from biological and synthetic sources, APVMA (veterinary equivalent of the TGA) license for manufacture of sterile immunobiological products, OGTR license to produce products from genetically modified organisms, and a DAF facility license for import and use of biologic materials. Additional information about AcuraBio is available at www.acurabio.com.About Ampersand Capital PartnersFounded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience in seeking to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. Additional information about Ampersand is available at www.ampersandcapital.com. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More